Cantor Fitzgerald restated their buy rating on shares of Horizon Pharma (NASDAQ:HZNP) in a report released on Wednesday. The firm currently has a $17.00 target price on the biopharmaceutical company’s stock.
“Message in a bottle/vial. The four doctors we spoke with were positive on the safety and efficacy of Horizon’s Krystexxa. One of the four doctors believed that Krystexxa was a ‘wonder’ drug and was bullish on its growth prospects. The other three doctors were more measured. They all agreed that Krystexxa is a very good drug, but were not convinced it would be widely used among rheumatologists because it works best for a small group of refractory patients. The main barrier to uptake is not anaphylaxis. There are two reasons doctors don’t widely use Krystexxa: 1) the high cost relative to standard of care; 2) because it’s an IV, while the standard of care is oral.”,” Cantor Fitzgerald’s analyst commented.
Several other equities research analysts have also commented on HZNP. ValuEngine lowered Horizon Pharma from a buy rating to a hold rating in a research note on Tuesday. Piper Jaffray Companies restated a buy rating and issued a $22.00 price objective on shares of Horizon Pharma in a research note on Thursday, March 1st. Cowen restated a buy rating and issued a $24.00 price objective on shares of Horizon Pharma in a research note on Thursday, March 1st. Morgan Stanley upped their price objective on Horizon Pharma from $14.00 to $16.00 and gave the stock an equal weight rating in a research note on Friday, March 2nd. Finally, BidaskClub upgraded Horizon Pharma from a sell rating to a hold rating in a research note on Saturday, March 3rd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $18.64.
Horizon Pharma (NASDAQ HZNP) traded down $0.18 during trading hours on Wednesday, hitting $15.13. The stock had a trading volume of 176,740 shares, compared to its average volume of 1,847,355. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.63 and a quick ratio of 1.54. The stock has a market cap of $2,509.69, a price-to-earnings ratio of -6.02, a price-to-earnings-growth ratio of 0.65 and a beta of 1.34. Horizon Pharma has a 52-week low of $9.45 and a 52-week high of $16.02.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.22 by $0.07. The firm had revenue of $274.22 million during the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. Horizon Pharma’s revenue was down 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 EPS. research analysts anticipate that Horizon Pharma will post 1.43 earnings per share for the current year.
Hedge funds have recently modified their holdings of the business. Advantage Investment Management LLC increased its stake in Horizon Pharma by 164.8% in the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,900 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new stake in Horizon Pharma in the 4th quarter worth $160,000. K2 Principal Fund L.P. increased its stake in Horizon Pharma by 126.1% in the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 53,574 shares in the last quarter. Zeke Capital Advisors LLC purchased a new stake in Horizon Pharma in the 4th quarter worth $167,000. Finally, Brown Advisory Inc. purchased a new stake in Horizon Pharma in the 3rd quarter worth $145,000. Institutional investors and hedge funds own 86.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Horizon Pharma (HZNP) Given Buy Rating at Cantor Fitzgerald” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://ledgergazette.com/2018/03/15/horizon-pharma-hznp-given-buy-rating-at-cantor-fitzgerald.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.